highli
pathogen
avian
influenza
hpai
extrem
contagi
multiorgan
system
diseas
one
among
multipl
subtyp
influenza
viru
virus
caus
laboratoryconfirm
infect
countri
fatal
result
fatal
rate
approxim
sinc
consid
potenti
seriou
pandem
threat
clinic
observ
indic
acut
lung
injuri
multipl
organ
dysfunct
direct
caus
death
human
laboratori
find
reveal
low
peripher
blood
tlymphocyt
count
high
chemokin
cytokin
level
individu
particularli
die
level
mig
chemoattract
monocyt
macrophag
produc
bronchial
epitheli
cell
alveolar
macrophag
elev
patient
avian
human
subtyp
influenza
higher
individu
particularli
high
die
level
neutrophil
chemoattract
interleukin
il
also
elev
individu
particularli
die
chemokin
produc
bronchial
epitheli
cell
may
function
pathogenesi
acut
respiratori
distress
syndrom
ard
may
particularli
relev
influenza
progress
respiratori
failur
associ
develop
ard
clinic
patholog
featur
human
anim
model
suggest
high
level
viral
replic
combin
earli
robust
host
respons
play
key
role
pneumonia
sever
outcom
innat
immun
respons
cell
first
line
defenc
virus
increas
evid
point
key
role
innat
immun
system
pattern
recognit
receptor
prr
infecti
noninfecti
lung
diseas
acut
lung
injuri
pneumoconiosi
asthma
prr
wellknown
tolllik
receptor
tlr
express
alveolar
macrophag
lung
epitheli
cell
intraepitheli
dendrit
cell
dc
either
locat
cell
surfac
endosom
membran
cell
respond
infect
sens
pathogenassoci
molecular
pattern
pamp
respond
endogen
molecul
dangerassoci
molecular
pattern
damp
releas
tissu
damag
tlr
recruit
differ
adapt
molecul
initi
signal
pathway
lead
activ
proinflammatori
gene
express
andor
type
interferon
ifnab
express
analysi
section
human
respiratori
tract
demonstr
attach
apic
cell
membran
bronchiolar
cell
type
ii
pneumocyt
alveolar
macrophag
therefor
activ
tlr
express
type
ii
pneumocyt
could
help
mediat
respons
virus
contribut
promot
destruct
host
immun
although
neuraminidas
inhibitor
effect
treat
avian
influenza
especi
given
within
h
infect
difficult
prevent
result
hypercytokinemia
develop
patient
seek
time
medic
assist
corticosteroid
use
patient
hpai
definit
role
steroid
determin
evid
corticosteroid
use
sever
viral
pneumonia
includ
varicellazost
viru
infect
sever
acut
respiratori
syndrom
sar
also
insuffici
sever
studi
involv
patient
sepsi
ard
suggest
highdos
corticosteroid
actual
increas
risk
secondari
infect
thu
urgent
need
find
way
treat
acut
hypercytokinemia
without
compromis
overal
immun
hemagglutinin
major
surfac
glycoprotein
respons
viral
bind
host
receptor
initi
immedi
signal
transduct
upon
viral
invas
recombin
ha
avian
influenza
viru
aiv
use
present
studi
investig
signal
transduct
mechan
dysregul
innat
immun
reaction
demonstr
challeng
respiratori
epitheli
cell
ha
exploit
signal
axi
result
larg
releas
cytokin
initi
destruct
innat
immun
respons
earli
stage
addit
found
select
inhibitor
target
key
signal
molecul
inflammatori
signal
cascad
potenti
role
treatment
inflammatori
disord
therebi
protect
superinflammatori
respons
pamp
attack
cultur
human
pulmonari
epitheli
cell
challeng
recombin
ha
h
stimul
cell
becam
swollen
round
irregular
size
shape
appear
intracellular
vacuol
figur
wherea
control
cell
figur
next
test
recombin
ha
could
induc
activ
jakstat
signal
pathway
respons
transcript
activ
chemokinescytokin
gene
lead
innat
immun
respons
pathogen
found
cell
expos
ha
increas
level
phosphoryl
figur
data
shown
timedepend
manner
previou
studi
demonstr
phosphoryl
dimeris
transloc
nucleu
activ
transcript
number
gene
includ
ifn
regulatori
function
transcript
factor
mani
antivir
gene
result
product
chemokin
eg
play
critic
role
infiltr
leukocyt
site
inflamm
addit
dimer
bind
site
within
promot
gene
therefor
examin
transcript
gene
hachalleng
cell
expect
result
show
increas
transcript
induct
gene
follow
ha
exposur
figur
correspondingli
detect
dosedepend
releas
rant
cultur
supernat
cell
h
ha
stimul
shown
figur
compar
ifntrigg
jakstat
pathway
activ
seem
characterist
featur
hatrigg
jakstat
signal
therefor
examin
target
could
block
induct
transcript
activ
ha
shown
figur
b
demonstr
abil
inhibitor
vi
calbiochem
attenu
phosphoryl
suppress
activ
figur
cell
challeng
ha
thu
block
induct
gene
express
figur
addit
also
observ
significantli
lower
level
cytokineschemokin
includ
rant
hastimul
cell
follow
treatment
inhibitor
vi
compar
ha
stimul
alon
figur
confirm
activ
enhanc
hadriven
innat
immun
knockout
mice
subject
challeng
intratrach
instil
ha
lung
tissu
hachalleng
mice
patholog
examin
observ
diffus
alveolar
damag
combin
edema
interstiti
exud
hyalin
membran
format
mark
thicken
interalveolar
septa
dens
interstiti
infiltr
inflammatori
cell
figur
howev
hachalleng
mice
figur
mice
treat
inhibitor
prior
ha
addit
figur
show
signific
decreas
inflammatori
cell
infiltr
mild
injuri
score
figur
addit
observ
spleen
tissu
mice
h
ha
intratrach
instil
exhibit
swell
destruct
local
structur
germin
centr
dead
lymphocyt
figur
c
chang
observ
mice
appear
normal
despit
ha
treatment
figur
f
compar
control
level
induc
chemokinescytokin
eg
rant
releas
splenocyt
mice
significantli
increas
basal
condit
p
figur
effect
seen
mice
ha
pretreat
signific
differ
detect
express
level
chemokin
mice
follow
either
pb
ha
instil
figur
previou
studi
demonstr
cytokin
signal
requir
optim
product
differenti
cell
primari
cell
prolifer
cell
cycl
regul
vitro
suggest
signal
promot
maxim
transcript
gene
taken
togeth
data
indic
activ
signal
ha
critic
role
induc
intens
host
respons
given
inhibitor
vi
capabl
downregul
activ
pulmonari
epitheli
cell
expos
ha
challeng
test
whether
target
signal
could
prevent
superinflammatori
respons
follow
bacteriaendotoxin
attack
test
due
natur
cours
viru
highli
cytopath
bronchial
bronchiolar
epitheli
cell
extend
rapidli
diffus
respiratori
tree
damag
epithelium
suffici
breakdown
mucociliari
barrier
mice
intratrach
inocul
ha
pb
h
instil
spleen
cell
isol
group
mice
cultur
presenc
absenc
bacteri
endotoxinlp
concentr
h
h
splenocyt
mice
pretreat
pb
stimul
lp
induc
increas
level
rant
figur
howev
significantli
elev
level
rant
observ
splenocyt
hapretr
mice
upon
lp
challeng
figur
significantli
higher
mice
mice
shown
figur
respons
lp
treatment
splenocyt
mice
ha
pretreat
produc
higher
level
chemokinescytokin
compar
pbspretreat
mice
mice
ha
pretreat
figur
made
comparison
fold
increas
induc
chemokinescytokin
group
mice
except
much
lower
fold
increas
chemokinescytokin
splenocyt
genet
defici
compar
wildtyp
figur
injuri
index
cultur
spleen
cell
h
figur
h
figur
lp
stimul
lpsdosedepend
higher
mice
mice
receiv
pb
pretreat
mice
receiv
ha
pretreat
p
figur
result
indic
sustain
cytokin
signal
follow
viru
antigen
challeng
predispos
anim
increas
virul
subsequ
bacteri
infect
respiratori
infect
highli
pathogen
influenza
virus
characteris
exuber
product
cytokin
chemokin
enhanc
recruit
innat
inflammatori
cell
although
alveolar
macrophag
origin
describ
cell
type
respons
pulmonari
monocyt
recruit
aiv
infect
recent
studi
herold
et
al
suggest
instead
major
recruit
result
alveolar
epitheli
cell
produc
high
level
ligand
follow
infect
result
agreement
find
show
activ
jakstat
signal
pathway
pulmonari
epitheli
cell
upon
challeng
ha
figur
lead
rapid
induct
gene
figur
addit
high
level
cytokineschemokin
produc
figur
data
may
repres
mechan
wherebi
viru
antigen
challeng
alveolar
epitheli
cell
constitut
initi
event
develop
dysregul
innat
immun
worthwhil
point
hatrigg
signal
event
characteris
unusu
process
involv
phosphoryl
janu
kinas
includ
cytoplasm
protein
tyrosin
kinas
play
import
role
receptor
bindingtrigg
signal
transduct
mediat
stat
protein
express
pattern
janu
kinas
contrast
sharpli
janu
kinas
ubiquit
express
found
limit
express
found
natur
killer
nk
cell
nklike
cell
line
rest
cell
tissu
present
studi
provid
evid
ha
treatment
immedi
caus
phosphoryl
cell
figur
mediat
releas
cytokineschemokin
figur
wherea
target
turn
signal
transduct
cascad
figur
result
suggest
induc
upon
activ
type
ii
pneumocyt
follow
activ
ha
pulmonari
epitheli
cell
activ
express
acquir
capabl
recruit
inflammatori
monocytederiv
dc
nk
cell
cell
due
significantli
increas
releas
cytokineschemokin
addit
show
mice
mice
ha
intratrach
instil
caus
acut
injuri
lung
figur
necrosi
deplet
lymphocyt
observ
spleen
figur
howev
splenocyt
hapretr
mice
shown
significantli
increas
product
ifninduc
chemokin
eg
without
stimul
figur
previous
demonstr
elev
emerg
onset
sar
follow
progress
lymphopenia
concomit
increas
lactat
dehydrogenas
suggest
deplet
lymphocyt
lymphoid
tissu
earli
onset
lymphopenia
pronounc
elev
cytokineschemokin
apoptot
lymphocyt
spleen
also
observ
patient
infect
influenza
viru
especi
sever
infect
data
indic
earli
splenic
lymphocyt
elimin
could
occur
due
excess
innat
immun
induct
depend
signal
activ
follow
antigen
challeng
might
contribut
high
level
viral
replic
activ
play
import
role
drive
inflammatori
respons
due
function
critic
transcript
activ
proinflammatori
cytokin
involv
innat
immun
respons
pampsdamp
present
studi
observ
signal
affect
transcript
activ
upon
ha
stimul
splenocyt
isol
mice
challeng
ha
display
resist
superinflammatori
reaction
expos
lp
figur
c
figur
b
indic
activ
express
might
associ
exacerb
lpsmediat
signal
present
result
provid
evid
inhibit
activ
enabl
neg
regul
signal
demonstr
molecular
determin
dysregul
innat
immun
respons
previou
studi
use
global
immun
suppress
steroid
fail
demonstr
protect
lethal
influenza
viru
challeng
surpris
nonspecif
immun
suppress
confer
advantag
system
reduct
cellmedi
immun
greatli
compromis
viru
clearanc
recent
studi
demonstr
combin
therapi
consist
inhibitor
viral
neuraminidas
zanamvir
two
cyclooxygenas
inhibitor
celecoxib
mesalazin
greatli
increas
surviv
rate
mice
infect
highli
pathogen
strain
influenza
viru
aldridg
et
al
recent
report
prophylact
treatment
agonist
pioglitazon
suffici
reduc
morbid
mortal
associ
hp
influenza
viru
infect
select
inhibitor
consid
immunomodul
extens
applic
potenti
specif
without
induc
mani
side
effect
usual
caus
corticosteroid
phase
ii
clinic
trial
prove
efficaci
safeti
inhibit
prevent
transplant
reject
elimin
symptom
rheumatoid
arthriti
psoriasi
similar
structur
inhibitor
vi
use
studi
current
undergo
phase
iii
studi
patient
activ
rheumatoid
arthriti
research
found
strongli
inhibit
transcript
rant
mig
day
posttranspl
similar
effici
inhibitor
vi
modul
proinflammatori
cytokineschemokin
observ
vitro
vivo
present
studi
figur
cell
prolifer
follow
activ
essenti
aspect
adapt
immun
respons
pathogen
cell
stimul
condit
prolifer
cytokin
independ
select
inhibit
cytokin
signal
affect
cell
cycl
progress
follow
optim
stimul
cell
receptor
plu
could
explain
find
genet
defici
protect
splenic
lymphocyt
intens
immunemedi
destruct
figur
presum
patient
sever
viral
infect
may
benefit
treatment
select
inhibitor
modul
dysregul
cytokinemedi
inflamm
allow
cell
prolifer
adapt
immun
respons
pathogen
clear
influenza
virus
iav
induc
defect
respiratori
mucos
immun
broadbas
advers
affect
respons
wide
rang
bacteria
interact
infect
viru
secondari
infect
due
bacteria
colonis
upper
respiratori
tract
could
precipit
appear
sever
potenti
fatal
bacteri
pneumonia
find
show
superinflammatori
respons
lp
pamp
splenocyt
mice
pretreat
ha
figur
rais
possibl
follow
viral
antigen
challeng
bacteriaendotoxin
transloc
prolong
boost
cytokin
signal
lead
fatal
system
inflammatori
respons
syndrom
thu
suggest
optim
treatment
virusmedi
ard
orand
system
inflamm
may
involv
combin
therapi
efficacybas
antivir
reagent
select
inhibitor
eg
inhibitor
summari
found
challeng
pulmonari
epitheli
cell
ha
strain
influenza
viru
result
remark
activ
innat
immun
respons
via
trigger
ifnindepend
jakstat
signal
pathway
may
key
mechan
underli
develop
lung
damag
lymphocyt
apoptosi
avoid
immunosurveil
facilit
effici
viral
replic
earli
stage
ill
seem
serv
central
signal
molecular
transduct
superactiv
immun
respons
aipamp
suggest
modul
abnorm
innat
immun
inflamm
use
select
inhibitor
could
novel
valuabl
strategi
manag
aiassoci
sever
pneumonia
immun
suppress
even
though
antivir
therapi
import
first
step
recoveri
baculoviru
express
system
produc
high
yield
recombin
protein
usual
similar
structur
biolog
activ
immunolog
reactiv
natur
occur
protein
insectbaculoviru
express
system
use
express
recombin
ha
protein
aiv
use
method
describ
nwe
et
al
minor
modif
use
sequenc
homolog
confirm
ha
gene
genbank
subclon
pfastbacht
plasmid
vector
form
recombin
next
transposit
combin
baculoviru
shuttl
vector
bacmid
max
effici
compet
cell
homolog
recombin
predict
bacmidha
recombin
identifi
pcr
amplif
kb
dna
fragment
figur
follow
recombin
use
nickel
affin
magnet
bead
recombin
ha
kda
purifi
cell
transfect
identifi
western
blot
antiha
antibodi
cat
geneimmun
inc
shown
figur
c
mice
mice
purchas
jackson
lab
unit
state
mice
hous
constant
temperatur
lightdark
photoperiod
allow
food
water
ad
libitum
mice
week
age
weigh
gram
anim
experi
carri
accord
nation
institut
health
guid
care
use
laboratori
anim
approv
bioethic
committe
state
key
laboratori
respiratori
diseas
guangzhou
medic
univers
approv
id
briefli
wildtyp
knockout
mice
randomli
divid
two
group
n
anaesthetis
pentobarbit
sodium
mgkg
mice
intratrach
inocul
ha
dilut
phosphatebuff
salin
pb
control
group
receiv
equal
volum
sterilis
salin
without
ha
lung
spleen
tissu
mice
collect
h
ha
inocul
fix
buffer
paraformaldehyd
ph
histopatholog
examin
cell
human
alveolar
epitheli
cell
line
atcc
usa
grown
polystyren
flask
dmem
gibco
usa
supplement
heatinactiv
foetal
bovin
serum
fb
gibco
ny
usa
cell
seed
cell
per
well
flatbottom
cell
cultur
plate
corn
ny
usa
produc
confluent
monolay
overnight
incub
humidifi
atmospher
next
growth
medium
replac
serumfre
dmem
medium
incub
overnight
cultur
cell
either
treat
ha
inhibitor
vi
nm
min
prior
ha
addit
supernat
collect
h
incub
ha
differ
concentr
store
cytokinechemokin
detect
spleen
remov
mice
mice
intratrach
inocul
ha
h
spleen
mechan
disrupt
press
nylon
mesh
pore
size
deposit
flask
contain
ml
rpmi
invitrogen
life
technolog
suspens
pass
steril
nylon
mesh
pore
size
obtain
splenocyt
lysi
erythrocyt
treatment
buffer
pool
splenocyt
suspend
complet
tissu
cultur
medium
consist
rpmi
supplement
heatinactiv
fb
invitrogen
life
technolog
uml
penicillin
streptomycin
cell
lyse
ripa
buffer
mm
tri
ph
mm
nacl
sd
mm
edta
mm
mm
pmsf
aprotinin
leupeptin
lysat
clear
centrifug
supernat
store
aliquot
use
protein
quantifi
use
bca
assay
kit
pierc
usa
use
sdspage
electrophoresi
protein
transfer
gel
onto
polyvinyliden
fluorid
membran
dupontnew
england
nuclear
boston
membran
block
nonfat
dri
milk
trisbuff
salin
h
follow
incub
membran
nonfat
dri
milk
contain
primari
antibodi
overnight
immunodetect
target
protein
perform
primari
antibodi
total
phosphoryl
cell
signal
frankfurt
germani
wash
secondari
antibodi
goatantirabbit
igg
conjug
hrp
cell
signal
frankfurt
germani
ad
incub
addit
h
immunoreact
band
develop
use
ecl
chemiluminesc
substrat
pierc
rockford
usa
digit
scan
perform
imag
station
kodak
us
experi
gapdh
novu
biolog
usa
detect
simultan
confirm
equal
protein
load
treatment
ha
vehicl
indic
period
cell
harvest
total
rna
isol
use
trizol
reagent
invitrogen
revers
transcript
reaction
conduct
use
iii
revers
transcript
reagent
invitrogen
amplifi
previous
gener
cdna
pcr
use
follow
specif
primer
gapdh
forward
aggaacctccagtctcagca
revers
ggcagtggaagtccatgaag
forward
cttaagaacccggcaacctctgccttc
revers
gapdh
forward
ggtgaaggtcggagtcaacg
revers
product
size
bp
bp
bp
respect
primer
purchas
invitrogen
california
usa
pcr
amplif
perform
use
biometra
tgradient
thermal
cycler
nordic
biosit
sweden
use
follow
protocol
reaction
predenatur
denatur
cycl
cycl
pcr
amplicon
analys
agaros
gel
stain
ethidium
bromid
subsequ
visualis
confirm
use
equal
amount
rna
experi
sampl
assess
gapdh
mrna
express
quantif
multipl
cytokineschemokin
perform
use
luminex
assay
liquidchip
system
panom
ca
usa
beadbas
system
immunoassay
allow
simultan
assay
multipl
analyt
singl
sampl
cytokineschemokin
includ
tumour
necrosi
factor
macrophag
inflammatori
protein
alpha
regul
upon
activ
normal
cell
express
secret
rant
supernat
hatreat
cell
analys
liquidchip
system
accord
manufactur
instruct
isol
splenocyt
mice
without
ha
pretreat
subject
cultur
absenc
presenc
lipopolysaccharid
lp
h
h
cultur
supernat
splenocyt
collect
liquidchip
assay
analysi
light
microscopi
lung
spleen
tissu
fix
freshli
prepar
paraformaldehyd
pb
ph
h
embed
paraffin
tissu
section
stain
haematoxylin
eosin
h
e
enabl
histolog
evalu
lung
spleen
tissu
two
investig
blind
group
assign
analys
sampl
determin
level
lung
injuri
accord
semiquantit
score
outlin
lung
field
examin
sampl
magnif
assess
histolog
lung
injuri
perform
follow
normal
lung
section
exhibit
interstiti
congest
inflammatori
cell
infiltr
lung
section
exhibit
interstiti
congest
inflammatori
cell
infiltr
lung
section
exhibit
consolid
inflammatori
cell
infiltr
mean
score
use
comparison
group
isol
spleen
cell
per
well
seed
tissu
cultur
plate
stimul
lp
differ
concentr
pb
h
monosodium
salt
cellcount
dojindo
molecular
technolog
inc
gaithersburg
md
per
well
ad
describ
previous
plate
incub
h
optic
densiti
od
nm
measur
use
micropl
reader
biorad
hercul
ca
sampl
analys
three
replic
injuri
index
calcul
use
follow
formula
injuri
index
mean
od
control
group
mean
od
control
group
comparison
among
treatment
group
perform
onewayanova
test
p
valu
less
consid
statist
signific
